2024 TB DRUG DOSING CHART FOR CHILDREN / ADOLESCENTS < 16 YEARS

WITH CONFIRMED/CLINICALLY DIAGNOSED DRUG-SUSCEPTIBLE/PRESUMED DRUG-SUSCEPTIBLE NON-SEVERE TB, SEVERE PULMONARY TB AND EXTRAPULMONARY TB (EPTB) excluding TB meningitis / central nervous system (CNS) TB / miligry TB (refer to chart on next page)

*Non-severe TB = intrathoracic lymph node TB without airway obstruction, simple TB pleural effusion (i.e. NOT loculated effusion/empyema/associated pneumothorax), isolated perihilar opacities, consolidation involving less than an entire lobe with no cavities or miliary pattern, or isolated cervical lymph node TB Severe pulmonary TB = children & adolescents <16 years who do not meet the criteria for non-severe TB

Treatment phase	Intensive phase Once daily, 7 days a week		Continuation phase Once daily, 7 days a week		Treatment phase	
Duration	2 months		*Non- severe TB 2 months	Severe PTB & most EPTB 4 months	Bone & joint TB 10 months	Duration
Target dose (range)	Isoniazid (H): 10 (7-15) mg/kg; Rifampicin (R): 15 (10 - 20) mg/kg; Pyrazinamide (Z): 35 (30 – 40) mg/kg; Ethambutol (E): 20 (15 – 25) mg/kg					
	HRZ	E	HR			
Body weight (kg)	50/75/150 mg dispersible tablet (scored) OR 50/75/150 mg/4 ml suspension ¹	400 mg tablet (not scored) <u>OR</u> 400 mg/8ml suspension ²	50/75 mg Dispersible tablet (scored) <u>OR</u> 50/75 mg/4 ml suspension ¹		Body weight (kg)	
<2	Obtain expert advice					
2 – 2.9	½ tab	1 ml	½ tablet			2 – 2.9
3 – 3.9	¾ tablet (3 ml)1	1.5 ml	¾ tablet (3 r	ml)1		3 – 3.9
3 – 3.9 4 – 7.9	3/4 tablet (3 ml)1 1 tablet	1.5 ml 2.5 ml	3/4 tablet (3 r 1 tablet	ml)1		3 – 3.9 4 – 7.9
3 – 3.9 4 – 7.9 8 – 11.9	% tablet (3 ml) ¹ 1 tablet 2 tablets	1.5 ml 2.5 ml ½ tablet or 4 ml	34 tablet (3 r 1 tablet 2 tablets	nl)¹		3 – 3.9 4 – 7.9 8 – 11.9
3 – 3.9 4 – 7.9 8 – 11.9 12 – 15.9	% tablet (3 ml) ¹ 1 tablet 2 tablets 3 tablets	1.5 ml 2.5 ml ½ tablet or 4 ml ¾ tablet or 6 ml	3/4 tablet (3 r 1 tablet 2 tablets 3 tablets	nl)¹		3 – 3.9 4 – 7.9 8 – 11.9 12 – 15.9
3-3.9 4-7.9 8-11.9 12-15.9 16-24.9	% tablet (3 ml) ¹ 1 tablet 2 tablets	1.5 ml 2.5 ml ½ tablet or 4 ml	3/4 tablet (3 r 1 tablet 2 tablets 3 tablets 4 tablets			3 - 3.9 4 - 7.9 8 - 11.9 12 - 15.9 16 - 24.9
3 – 3.9 4 – 7.9 8 – 11.9 12 – 15.9	% tablet (3 ml) ¹ 1 tablet 2 tablets 3 tablets	1.5 ml 2.5 ml ½ tablet or 4 ml ¾ tablet or 6 ml 1 tablet or 8 ml	3/4 tablet (3 r 1 tablet 2 tablets 3 tablets 4 tablets Choose one	of the below o		3 – 3.9 4 – 7.9 8 – 11.9 12 – 15.9
$ \begin{array}{r} 3 - 3.9 \\ 4 - 7.9 \\ 8 - 11.9 \\ 12 - 15.9 \\ 16 - 24.9 \\ $	3/4 tablet (3 ml) ¹ 1 tablet 2 tablets 3 tablets 4 tablets HRZE (75/150/400/	1.5 ml 2.5 ml ½ tablet or 4 ml ¾ tablet or 6 ml 1 tablet or 8 ml	3/4 tablet (3 m 1 tablet 2 tablets 3 tablets 4 tablets Choose one HR 75/150 m	of the below ong tab HR 150	0/300 mg tab	$ 3-3.9 4-7.9 8-11.9 12-15.9 16-24.9 \geq 25$
$ 3-3.9 4-7.9 8-11.9 12-15.9 16-24.9 \geq2525-29.9 $	% tablet (3 ml) ¹ 1 tablet 2 tablets 3 tablets 4 tablets HRZE (75/150/400/2)	1.5 ml 2.5 ml ½ tablet or 4 ml ¾ tablet or 6 ml 1 tablet or 8 ml	3/4 tablet (3 m 1 tablet 2 tablets 3 tablets 4 tablets Choose one HR 75/150 m 2 tablets	of the below o	0/300 mg tab	$ 3-3.9 4-7.9 8-11.9 12-15.9 16-24.9 \geq2525-29.9$
$ \begin{array}{r} 3 - 3.9 \\ 4 - 7.9 \\ 8 - 11.9 \\ 12 - 15.9 \\ 16 - 24.9 \\ $	3/4 tablet (3 ml) ¹ 1 tablet 2 tablets 3 tablets 4 tablets HRZE (75/150/400/	1.5 ml 2.5 ml ½ tablet or 4 ml ¾ tablet or 6 ml 1 tablet or 8 ml	3/4 tablet (3 m 1 tablet 2 tablets 3 tablets 4 tablets Choose one HR 75/150 m	of the below ong tab HR 150	D/300 mg tab	$ 3-3.9 4-7.9 8-11.9 12-15.9 16-24.9 \geq 25$

¹ To make an oral suspension, for weight band 3 - 3.9 kg, for each dose, disperse 1 x HRZ 50/75/150 mg tablet (2 months intensive phase) or 1 x HR 50/75 mg tablet (continuation phase) in 4 ml of water, administer 3 ml, discard unused suspension. For other weight bands, an oral suspension can be made by dispersing the required number of tablets & fractions of tablets in a small amount of water (5-10 ml) and administering all of the suspension to the child orally or via nasogastric tube.

CHILDREN SHOULD BE TAUGHT AND ENCOURAGED TO SWALLOW WHOLE TABLETS OR, IF REQUIRED, FRACTIONS OF TABLETS SO AS TO AVOID LARGE VOLUMES OF LIQUID MEDICATION









Based on the 2024 NDoH Management of Tuberculosis in Children and Adolescents: A Clinical Guideline For The Diagnosis and Treatment of Drug-susceptible TB in Children and Adolescents in South Africa, September 2024

*ELIGIBILITY CRITERIA FOR SHORTER 2 MONTHS CONTINUATION PHASE: ALL CRITERIA SHOULD BE MET

AT DIAGNOSIS Clinical

- 3 months <16 years at start of TB treatment
- Drug-susceptible pulmonary TB or cervical TB lymphadenitis (& no other extrapulmonary TB)
- First episode of TB treatment
- No danger signs# indicating severe illness at presentation
- No severe acute malnutrition
- No asymmetric or persistent wheezing
- If living with HIV, must be on ART for at least 3 months with viral load <1000 at TB diagnosis or in the previous 3 months
- If no CXR available at start of TB treatment, must be 3 months - <8 years, HIV negative and no acid-fast bacilli smear positive respiratory samples (if done)

Radiological – NONE of the following should be present

- Complicated intra-thoracic lymph node TB (airway compression/deviation and/or hyperinflation/collapse)
- Consolidation involving ≥1 lobe
- Complicated pleural effusion (loculated effusion, empyema, pneumothorax)
- Miliary pattern
- Cavities

AT FOLLOW-UP Clinical

- Adherent to treatment
- Month 1: all TB symptoms & signs improved including weight
- Month 4: all TB symptoms and signs resolved & improving weight trend

Those not meeting the eligibility criteria should receive 4 months continuation phase (or 10 months for bone & joint TB) # Refer to Table on next page

NEED HELP?

Contact the TOLL-FREE National HIV &TB Health Care Worker Hotline 0800 212 506 /021 406 6782

Alternatively "WhatsApp" or send an SMSor "Please Call Me to 0.71 840 1572 www.mic.uct.ac.za



² If oral suspension required, for each dose, crush 1 x ethambutol 400 mg tablet to a fine powder, disperse in 8 ml of water to prepare a concentration of 400 mg/8 ml (50 mg/ml), administer required dose as indicated in above chart, discard unused suspension.

2024 TB DRUG DOSING CHART FOR CHILDREN / ADOLESCENTS < 16 YEARS

WITH CONFIRMED/PRESUMED DRUG-SUSCEPTIBLE
TB MENINGITIS / CENTRAL NERVOUS SYSTEM (CNS) TB / MILIARY TB

Single phase of treatment: 6-9 months Once daily, 7 days a week								
Target dose range & maximum doses	Isoniazid (H): 15-20 mg/kg, maximum dose 450 mg Rifampicin (R): 22.5-30 mg/kg, maximum dose 900 mg	Pyrazinamide (Z): 35-45 mg/kg, maximum dose 2 g	17.5-22.5 mg/kg,	Target dose range & maximum doses				
Formulation	HR	Z	Eto	Formulation				
	50/75 mg	500 mg	250 mg					
Body	dispersible tablet (scored)	tablet (scored)	tablet (not scored)	Body				
weight	OR	OR	OR	weight				
(kg)	50/75 mg/4 ml suspension ³	500 mg/8 ml suspension ⁴	250 mg/8 ml suspension ⁵	(kg)				
<2	Obtair	<2						
2 – 2.9	¾ tablet (3 ml) ³	1 ml	1.5 ml	2 – 2.9				
3 – 3.9	1 ½ tablets	2 ml	2 ml	3 – 3.9				
4 – 4.9	<3 months: 1 ½ tablets ≥3 months: 2 tablets	2.5 ml	2.5 ml	4 – 4.9				
5 - 5.9	2 ½ tablets	3 ml	3 ml	5 – 5.9				
6 – 7.9	3 tablets	½ tablet or 4 ml	½ tablet or 4 ml	6 – 7.9				
8 – 8.9	3 ½ tablets	72 TODICT OF 4 TH	72 IGDICT OF 4 ITII	8 – 8.9				
9 – 9.9	0 /2 1001013	¾ tablet or 6 ml	¾ tablet or 6 ml	9 – 9.9				
10 – 11.9	4 tablets			10 – 11.9				
12 – 12.9		1 tablet or 8 ml	1 tablet or 8 ml	12 – 12.9				
13 – 14.9 15 – 15.9	4 ½ tablets			13 – 14.9				
16 - 16.9	5 tablets			15 – 15.9 16 – 16.9				
17 – 17.9	6 tablets	1 ¼ tablets or 10 ml	1 74 Idblets of TO MI	17 – 17.9				
18 – 19.9	o lubieis			18 – 19.9				
20 – 24.9	7 tablets	1 ½ tablets	1 ½ tablets or 12 ml	20 – 24.9				
25 – 29.9	7 1001013	2 tablets	2 tablets or 16 ml	25 – 29.9				
30 – 34.9	HR	2 ½ tablets	2 ½ tablets or 20 ml	30 – 34.9				
35 – 39.9	150/300 mg tablet	3 tablets	3 tablets or 24 ml	35 – 39.9				
40 – 49.9	3 tablets	3 ½ tablets	3 ½ tablets or 28 ml	40 – 49.9				
≥50		4 tablets	4 tablets or 32 ml	≥50				

CHILDREN SHOULD BE TAUGHT AND ENCOURAGED TO SWALLOW WHOLE TABLETS OR, IF REQUIRED, FRACTIONS OF TABLETS TO AVOID LARGE VOLUMES OF LIQUID MEDICATION

- 3 To make an oral suspension for weight band $\underline{2}$ $\underline{2.9}$ kg, for each dose, disperse 1 x HR 50/75 mg tablet in $\mathbf{4}$ ml of water, administer 3 ml, discard unused suspension. For other weight bands, an oral suspension can be made by dispersing the required number of tablets & fractions of tablets in a small amount of water (5-10 ml) and administering all of the suspension to the child orally or via nasogastric tube.
- ⁴ To make an oral suspension, crush 1 x 500 mg pyrazinamide tablet to a fine powder, disperse in **8 ml** water to prepare a concentration of 500 mg/8 ml (62.5 mg/ml), administer required dose as indicated in above chart, discard unused suspension.
- ⁵ To make an oral suspension, crush 1 x 250 mg ethionamide tablet to a fine powder, disperse in **8 ml** of water to prepare a concentration of 250 mg/8 ml (31.3 mg/ml), administer required dose as indicated in above chart, discard unused suspension.

NEED HELP?

Contact the TOLL-FREE National HIV & TB Health Care

0800 212 506 /021 406 6782 Alternatively "WhatsApp" or send an SMS or "Please Call

> to 071 840 1572 www.mic.uct.ac.za





DANGER SIGNS INDICATING SEVERE ILLNESS AT PRESENTATION IN CHILDREN >3 MONTHS OF AGE Adapted from the WHO Operational handbook on TB Module 5, SA National 2022 IMCI guidelines and Chapter 15: Respiratory System of the STG and EML for paediatric hospitals in SA, 2013 Signs of severe dehydration Signs of meningitis Signs of severe General danger signs Signs of severe respiratory illness (any) anaemia (any) (two or more) (any) Vomiting everything Chest indrawing Unconscious or lethargic Neck stiffness Severe palmar pallor Convulsions Stridor in calm child Sunken eyes **Bulging fontanelle** • Hb <7 g/dl Oxygen saturation <92% in room air Unconscious or lethargic Unable to drink or drinking poorly Restless, continuously irritable Central cyanosis Skin pinch goes back very slowly Any signs of shock • Unable to drink/breastfeed